Development and application of receptor-modified T lymphocytes for adoptive immunotherapy

Transfusion Medicine Reviews

Volumn 15, Issue 1, 2001, Pages 21-34

  Geiger, Terrence L ^a,b   Divye Jyothi, M ^a  

^a Research Hospital   (United States)

^b Division of Virology Department of Infectious Diseases St Jude Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN BINDING; CELL TYPE; CELLULAR IMMUNITY; CONFERENCE PAPER; HUMORAL IMMUNITY; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 0035181589     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1053/tmrv.2001.19949     Document Type: Conference Paper

References (104)

1. Platelet GPIIb-IIIa blockers
2. Monoclonal antibody therapy of cancer
3. Immunotoxins in cancer therapy
4. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins
5. Developments with targeted enzymes in cancer therapy
6. Antibody phage display technology and its applications
7. Generation of recombinant antibodies
8. Pharmacokinetics and biodistribution of genetically-engineered antibodies
9. The application of gene therapy in autoimmune diseases
10. Potent antitumour activity of a new class of tumour-specific killer cells
11. Cell therapy: Achievements and perspectives
12. Donor lymphocyte infusions
13. Adoptive cellular immunotherapy for EBV lymphoproliferative disease
14. Principles for adoptive T cell therapy of human viral diseases
15. Processing and delivery of peptides presented by MHC class I molecules
16. MHC class II restricted antigen presentation
17. A cell culture model for T lymphocyte clonal anergy
18. Anergy as a mechanism of peripheral T cell tolerance
19. The minimal number of class II MHC-antigen complexes needed for T cell activation
20. From TCR engagement to T cell activation: A kinetic view of T cell behavior
21. Binding energetics of T-cell receptors: Correlation with immunological consequences
22. The T cell receptor/CD3 complex: A dynamic protein ensemble
23. Genetic and mutational analysis of the T-cell antigen receptor
24. New nomenclature for the RETH motif
25. Immunoreceptor tyrosine based activation motif (ITAM), a unique module linking antigen and Fc receptors to their signaling cascades
26. The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine protein kinase p56lck
27. Signal transduction by the lymphocyte-specific tyrosine protein kinase p56lck
28. T cell antigen receptor signal transduction pathways
29. ZAP-70 is essential for the T cell antigen receptor-induced plasma membrane targeting of SOS and vav in T cells
30. Association of the adaptor molecule LAT with CD4 and CD8 coreceptors identifies a new coreceptor function in T cell receptor signal transduction
31. The dynamics of T cell receptor signaling: Complex orchestration and the key roles of tempo and cooperation
32. Accessory molecules and costimulation requirements for CD4 T cells
33. Co-stimulation in T cell responses
34. Chimeric immunoglobulin-T cell receptor proteins form functional receptors: Implications for T cell receptor complex formation and activation
35. Expression of a hybrid immunoglobulin-T cell receptor protein in transgenic mice
36. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity
37. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor associated signal transduction pathways
38. T cell and basophil activation through the cytoplasmic tail of T cell receptor zeta family proteins
39. Sequence requirements for induction of cytolysis by the T cell antigen/Fc receptor zeta chain
40. Chimeric zeta receptors direct human natural killer effector function to permit killing of NK resistant tumor cells and HIV infected T lymphocytes
41. Turning on natural killer cells
42. Development and function of T cells in T cell antigen receptor/CD3 zeta knockout mice reconstituted with Fc epsilon RI gamma
43. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors
44. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain
45. The T-cell-receptor ζ chain is sufficient for the activation and maturation of primary T lymphocytes
46. Role of TCR ζ chain in T cell development and selection
47. Crippling of CD3-zeta ITAMs does not impair T cell receptor signaling
48. Role of multiple T cell receptor (TCR)-ζ chain signaling motifs in selection of the T cell repertoire
49. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product
50. The emerging role of CTLA-4 as an immune attenuator
51. Cytotoxic T lymphocyte antigen 4 (CTLA-4) engagement delivers an inhibitory signal through the membrane-proximal region in the absence of the tyrosine motif in the cytoplasmic tail
52. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role for CTLA-4
53. The Syk family of protein tyrosine kinases in T-cell activation and development
54. Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: Optimal design for T cell activation
55. Direct T cell activation by chimeric single chain Fv-Syk promotes Syk-Cbl association and Cbl phosphorylation
56. Tyrosine-phosphorylated T cell receptor zeta chain associates with the actin cytoskeleton upon activation of mature T lymphocytes
57. Generating improved single-chain Fv molecules for tumor targeting
58. Chimaeric T-cell receptors specific to a B-lymphoma idiotype: A model for tumour immunotherapy
59. Tumor-specific T-bodies: Towards clinical application
60. Impact of chimeric immune receptor extracellular protein domains on T cell function
61. The role of T-cell receptor dimerization in T-cell activation
62. Transmembrane helical interactions: Zeta chain dimerization and functional association with the T cell receptor
63. Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules
64. Cellular immunity to HIV activated by CD4 fused to T cell receptor polypeptides
65. Lysis of HIV-1 infected cells and inhibition of viral replication by universal receptor T cells
66. Structure, specificity and CDR mobility of a class II restricted single-chain T-cell receptor
67. Alanine scanning mutagenesis of an alphabeta T cell receptor: Mapping the energy of antigen recognition
68. Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production
69. Carbohydrate recognition on MUC1-expressing targets enhances cytotoxicity of a T cell subpopulation
70. MUC1 and cancer
71. Ganciclovirsensitive acute graft-versus-host disease in mice receiving herpes simplex virus-thymidine kinase-expressing donor T cells in a bone marrow transplantation setting
72. Synthetic activation of caspases: Artificial death switches
73. Pharmacological control of antigen responsiveness in genetically modified T lymphocytes
74. Generation of conditional mutants in higher eukaryotes by switching between the expression of two genes
75. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors
76. Biotechnological and gene therapeutic strategies in cancer treatment
77. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes
78. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells
79. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression
80. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA
81. Carcinoembryonic antigen
82. The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer
83. Bypassing immunization: Optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA
84. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers
85. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes
86. The CD44 proteins in embryonic development and in cancer
87. Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:zeta-chimera
88. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes
89. Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis
90. A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes
91. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen
92. Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor
93. Long-term survivors of HIV-1 infection
94. Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans
95. Characterization of T cell-expressed chimeric receptors with antibody-type specificity for the CD4 binding site of HIV-1 gp120
96. Lysis of HIV-1 infected cells and inhibition of viral replication by universal receptor T cells
97. + T lymphocytes armed with universal T-cell receptors
98. Cellular immunity to HIV activated by CD4 fused to T cell receptor polypeptides
99. Gene therapy approaches to HIV-infection: Immunological strategies: Use of T bodies and universal receptors to redirect cytolytic T-cells
100. A phase I/II pilot study of the safety of the adoptive transfer of syngeneic gene-modified cytotoxic T lymphocytes in HIV-infected identical twins
101. Loss of original antigenic specificity in T cell hybridomas transduced with a chimeric receptor containing single-chain Fv of an anticollagen antibody and Fc epsilonRI-signaling gamma subunit
102. Systemic T cell-independent tumor immunity after transplantation of universal receptor-modified bone marrow into SCID mice
103. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains
104. Functional expression in mast cells of chimeric receptors with antibody specificity